Charles Schwab Investment Management Inc Neurocrine Biosciences Inc Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 762,557 shares of NBIX stock, worth $87.7 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
762,557
Previous 747,291
2.04%
Holding current value
$87.7 Million
Previous $86 Million
20.98%
% of portfolio
0.02%
Previous 0.02%
Shares
30 transactions
Others Institutions Holding NBIX
# of Institutions
650Shares Held
96.2MCall Options Held
380KPut Options Held
382K-
Black Rock Inc. New York, NY14.2MShares$1.63 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.16 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$563 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$347 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$292 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...